Bausch Health Companies Inc. (NYSE:BHC) Director Buys $5,392,473.52 in Stock

Bausch Health Companies Inc. (NYSE:BHC) Director John Paulson acquired 1,029,098 shares of the company’s stock in a transaction dated Wednesday, June 11th. The stock was purchased at an average cost of $5.24 per share, with a total value of $5,392,473.52. Following the completion of the purchase, the director now directly owns 28,222,267 shares of the company’s stock, valued at approximately $147,884,679.08. This represents a 3.78% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

John Paulson also recently made the following trade(s):

• On Thursday, June 12th, John Paulson acquired 1,005,376 shares of Bausch Health Companies stock. The stock was purchased at an average cost of $5.47 per share, with a total value of $5,499,406.72.
• On Tuesday, June 10th, John Paulson acquired 754,134 shares of Bausch Health Companies stock. The stock was purchased at an average cost of $5.05 per share, with a total value of $3,808,376.70.

Bausch Health Companies Price Performance

BHC opened at $6.02 on Friday. Bausch Health Companies Inc. has a 12 month low of $3.96 and a 12 month high of $9.85. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of -50.12, a PEG ratio of 0.37 and a beta of 0.28. The business has a fifty day moving average price of $4.85 and a 200 day moving average price of $6.42.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on BHC. Royal Bank of Canada lifted their price objective on Bausch Health Companies from $8.50 to $10.00 and gave the company a “sector perform” rating in a research note on Friday, May 2nd. Wall Street Zen cut Bausch Health Companies from a “buy” rating to a “hold” rating in a research note on Saturday, May 10th. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $7.42.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Nomura Holdings Inc. grew its stake in Bausch Health Companies by 106.2% during the 1st quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company’s stock worth $151,366,000 after purchasing an additional 12,050,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Bausch Health Companies by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company’s stock worth $76,152,000 after buying an additional 61,621 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Bausch Health Companies by 1.1% during the 4th quarter. Franklin Resources Inc. now owns 5,316,822 shares of the company’s stock worth $42,855,000 after buying an additional 56,446 shares during the last quarter. Maple Rock Capital Partners Inc. lifted its holdings in Bausch Health Companies by 156.7% during the 4th quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company’s stock worth $42,718,000 after buying an additional 3,235,100 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Bausch Health Companies by 46.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company’s stock worth $38,501,000 after buying an additional 1,510,445 shares during the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.